Patients with lung adenocarcinoma typically carry a mutation in the Epidermal Growth Factor Receptor (EGFR) gene, making them ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

The strategic worldwide licensing agreement grants Servier the rights to develop and commercialize BDTX-4933, a therapy currently in Phase 1 development. Under the terms of the deal, Black Diamond ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with ...

Patients with lung adenocarcinoma – the most common type of cancer among non-smokers -- carry a specific mutation in the ...

Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...

Exposure to wildfires during lung cancer recovery leads to longer hospital stays. This study highlights the need for disaster ...

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

Whitehawk Therapeutics, Inc. , formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Patanjali’s Renogrit effectively mitigates kidney damage caused by the cancer drug cisplatin, according to a study published ...